Multi-spanning membrane proteins are targets of half of all small molecule drugs but only 3 therapeutic monoclonal antibodies (MAbs).
THE INDUSTRY LEADER IN MEMBRANE PROTEIN SOLUTIONS
Integral Molecular Launches TiterSafe™ Influenza Virus-Like Particles for Safe and Convenient Vaccine Testing
11/7/2023
Integral Molecular Unveils Trispecific Molecules Targeting GPRC5D, BCMA, and CD3 for Multiple Myeloma
11/3/2023
Integral Molecular Secures Nearly $900K in NIH Funding for Antibody Discovery
10/5/2023
Systematic analysis of human antibody response to ebolavirus glycoprotein shows high prevalence of neutralizing public clonotypes
Cell Reports, 2023
Shark nanobodies with potent SARS-CoV-2 neutralizing activity and broad sarbecovirus reactivity
Nature Communications, 2023
Antibody specificity against highly conserved membrane protein Claudin 6 driven by single atomic contact point
iScience, 2022
THE INDUSTRY LEADER IN MEMBRANE PROTEIN SOLUTIONS
Why Are There So Few Therapeutic Antibodies Against Complex Membrane Proteins?
MAbs offer therapeutic advantages of exquisite specificity, safety, and bioavailability and are twice as likely as small molecules to succeed in clinical trials. However, due to the complex structure and high homology of membrane protein targets, MAbs against them are difficult to generate, isolate and characterize.
Integral Molecular Enables Membrane Protein Antibody Discovery
With a 95% success rate, Integral Molecular is the leader in isolating MAbs against complex membrane proteins, including GPCRs, ion channels, transporters and viral proteins.
INDUSTRY EXPERIENCE
With 20+ years experience, Integral Molecular is the industry leader in isolating and characterizing complex membrane proteins.
PROVEN QUALITY
Integral Molecular’s technologies have contributed to scientific discoveries featured in 400+ peer-reviewed publications.
OPEN COMMUNICATION
Your success is crucial to us. We work hard to understand your needs, and strive to exceed your expectations.
Membrane Protein Solutions
Our full suite of Membrane Protein Solutions delivers diverse panels of functional MAbs
Our virus-like particles contain high levels of native membrane proteins for better immunization and screening
Our Ala-scan epitope mapping service provides mechanism of action data and strengthens IP
We screen antibodies against 6,000 human membrane proteins for deorphaning and de-risking studies
Reporter Virus Particles and other tools to expedite vaccine and antibody development
Trusted by 500+ Companies
Ready To Get Started?
We have worked with more than 100 top biotech and pharmaceutical companies to help them succeed. Let’s talk about how we can help you.
